EVOK - Biotech Analysis Central Pharma News: Evoke's Mishap ImmunoGen's Struggle Eli Lilly's Priority Review
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Evoke Pharma Tumbles After Preliminary NDA Review
News: Recently, Evoke Pharma (EVOK) tumbled by 51% on the announcement that the FDA was not satisfied with the information it received in its initial NDA review for Gimoti. Specifically, the biotech received what is known as a multi-disciplinary review ((DR)) letter from the FDA. The basic premise is that this letter is given to a company in the preliminary stages of review to